VIALE-A: Venetoclax with or without in treatment-naïve patients with acute myelo...
Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA
VIALE-A: Venetoclax with or without in treatment-naïve patients with acute myeloid leukaemia ( Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA )
13 Jun 2020
AGMT_MM-1: Assessing the oral microbiome in patients with relapsed/refractory mu...
Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria
AGMT_MM-1: Assessing the oral microbiome in patients with relapsed/refractory multiple myeloma ( Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria )
13 Jun 2020
Investigating KRd versus KTd in NDMM patients with high-risk cytogenetics
Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria
Investigating KRd versus KTd in NDMM patients with high-risk cytogenetics ( Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria )
13 Jun 2020
GMMG-CONCEPT: Isa-KRd in front-line treatment of high-risk myeloma
Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, German...
GMMG-CONCEPT: Isa-KRd in front-line treatment of high-risk myeloma ( Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, Germany )
13 Jun 2020
CANDOR trial design: Investigating KdD versus Kd in relapsed/refractory multiple...
Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, German...
CANDOR trial design: Investigating KdD versus Kd in relapsed/refractory multiple myeloma ( Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, Germany )
13 Jun 2020
CANDOR updated results: KdD versus Kd in patients with RRMM according to prior l...
Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, German...
CANDOR updated results: KdD versus Kd in patients with RRMM according to prior lines of therapy ( Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, Germany )
13 Jun 2020
Patient reported outcomes for the CANDOR trial for multiple myeloma
Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, German...
Patient reported outcomes for the CANDOR trial for multiple myeloma ( Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, Germany )
13 Jun 2020
FORTE trial: Minimal residual disease evaluation in newly diagnosed multiple mye...
Dr Stefania Oliva - GIMEMA, European Myeloma Network, Italy
FORTE trial: Minimal residual disease evaluation in newly diagnosed multiple myeloma ( Dr Stefania Oliva - GIMEMA, European Myeloma Network, Italy )
11 Jun 2020
Comparing pevonedistat plus azacitidine versus azacitidine alone in patients wit...
Prof Lionel Ades - Hôpital Saint-Louis, Paris, France
Comparing pevonedistat plus azacitidine versus azacitidine alone in patients with higher-risk MDS/CMML or low-blast AML ( Prof Lionel Ades - Hôpital Saint-Louis, Paris, France )
11 Jun 2020
Timing of response to venetoclax combination treatment in older patients with ac...
Dr Brian Jonas - University of California Davis Comprehensive Cancer Center, Sac...
Timing of response to venetoclax combination treatment in older patients with acute myeloid leukaemia ( Dr Brian Jonas - University of California Davis Comprehensive Cancer Center, Sacramento, USA )
3 Jun 2020
Venetoclax with bortezomib and dexamethasone in relapsed/refractory multiple mye...
Dr Shaji Kumar - Mayo Clinic, Rochester, USA
Venetoclax with bortezomib and dexamethasone in relapsed/refractory multiple myeloma ( Dr Shaji Kumar - Mayo Clinic, Rochester, USA )
1 Jun 2020
KRd vs VRd for initial therapy of newly diagnosed multiple myeloma
Dr Shaji Kumar - Mayo Clinic, Rochester, USA
KRd vs VRd for initial therapy of newly diagnosed multiple myeloma ( Dr Shaji Kumar - Mayo Clinic, Rochester, USA )
1 Jun 2020